Login to Your Account

Yakult Honsha, 4SC to tackle liver cancer in Japanese patients

By Dan Poppy
Contributing Writer

Thursday, May 8, 2014
Japanese firm Yakult Honsha Co. Ltd. completed phase I trials for resminostat – licensed from German firm 4SC AG – in solid tumors, as the partners hope to move forward with the target indication of hepatocellular carcinoma (HCC) in Japan, where liver cancer is one of the largest causes of cancer-related death.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription